EN
TR
Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report
Öz
Selective serotonin reuptake inhibitors can lead to increased prolactin levels and galactorrhea. Herein, we reported a 40-year-old female patient who developed galactorrhea and hyperprolactinemia two weeks after initiation of fluoxetine 20 mg/day. Galactorrhea was discontinued after the fifth week of fluoxetine withdrawal and prolactin levels reached normal limits. The patient's depressive symptoms disappeared with citalopram 40 mg/day and no similar side effects were observed during follow-up. Clinicians should be aware of the hyperprolactinemia and galactorrhea adverse effects of fluoxetine.
Anahtar Kelimeler
Kaynakça
- Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168-175.
- Malik AA, Aziz F, Beshyah SA, Aldahmani KM. Aetiologies of hyperprolactinaemia: A retrospective analysis from a tertiary healthcare centre. Sultan Qaboos Univ Med J. 2019 May;19(2):e129-e134.
- Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29-36.
- Turkoglu S. Citalopram-induced galactorrhea in an adolescent. Clin Neuropharmacol. 2016;39(6):331.
- Evrensel A, Önen Ünsalver B, Akyol A, Ceylan ME. A case of galactorrhea during paroxetine treatment. Int J Psychiatry Med. 2016;51(3):302-305.
- Özten E, Hızlı-Sayar G, Göğcegöz-Gül I, Ceylan ME. Sertraline-induced galactorrhea. Arch Neuropsychiatr. 2015;52:202-203.
- Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc. 2001;76:215-216.
- Akdemir A, Örsel SD, Dağ İ, Türkçapar MH, İşcan N, Ozbay H. Hamilton depresyon derecelendirme ölçeği (HDDO)’nin geçerliliği-güvenilirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji (3P) Dergisi. 1996;4(4):251-259.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Psikiyatri
Bölüm
Olgu Sunumu
Yazarlar
Yayımlanma Tarihi
1 Mart 2021
Gönderilme Tarihi
27 Ekim 2020
Kabul Tarihi
15 Aralık 2020
Yayımlandığı Sayı
Yıl 2021 Cilt: 3 Sayı: 1
APA
Örüm, M. H. (2021). Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report. Phoenix Medical Journal, 3(1), 44-45. https://doi.org/10.38175/phnx.817248
AMA
1.Örüm MH. Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report. Phnx Med J. 2021;3(1):44-45. doi:10.38175/phnx.817248
Chicago
Örüm, Mehmet Hamdi. 2021. “Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report”. Phoenix Medical Journal 3 (1): 44-45. https://doi.org/10.38175/phnx.817248.
EndNote
Örüm MH (01 Mart 2021) Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report. Phoenix Medical Journal 3 1 44–45.
IEEE
[1]M. H. Örüm, “Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report”, Phnx Med J., c. 3, sy 1, ss. 44–45, Mar. 2021, doi: 10.38175/phnx.817248.
ISNAD
Örüm, Mehmet Hamdi. “Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report”. Phoenix Medical Journal 3/1 (01 Mart 2021): 44-45. https://doi.org/10.38175/phnx.817248.
JAMA
1.Örüm MH. Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report. Phnx Med J. 2021;3:44–45.
MLA
Örüm, Mehmet Hamdi. “Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report”. Phoenix Medical Journal, c. 3, sy 1, Mart 2021, ss. 44-45, doi:10.38175/phnx.817248.
Vancouver
1.Mehmet Hamdi Örüm. Fluoxetine-Induced Reversible Galactorrhea and Hyperprolactinemia: A Case Report. Phnx Med J. 01 Mart 2021;3(1):44-5. doi:10.38175/phnx.817248

